Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-345.2%-301pp-43.8%
Net margin-302.6%-271pp-31.2%
Returns
Return on equity-32.6%-15.7pp-16.9%
Return on invested capital-46.4%+12.6pp-59%
Efficiency
Asset turnover0.1×-0.2×0.3×-0.2×0.5×0.0×0.5×0.0×0.5×+0.3×
Liquidity
Current ratio9.5×+3.4×6.1×-0.4×6.5×-0.6×7.2×+1.5×5.6×+3.2×
Leverage
Debt-to-equity0.1×-0.1×0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×
Per Share
Book value per share$5.23+86.2%$2.81-6.0%$2.98-8.5%$3.26-1.7%$3.32+10.0%
Valuation
Market capitalization$1.32B+28.9%$1.02B+123%$457.64M+57.0%$291.56M+2.2%$285.41M-33.1%
Price / sales30.6×+22.4×8.3×+5.7×2.5×+0.9×1.6×-0.2×1.8×-3.8×
Price / book2.5×-1.9×4.4×+2.5×1.9×+0.8×1.1×+0.1×-0.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Monte Rosa Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.